比较利妥昔单抗与环磷酰胺诱导治疗儿童期抗中性粒细胞胞质抗体相关性血管炎:ARChiVe登记队列研究
该ARChiVe登记队列研究纳入104例儿童期肉芽肿性多血管炎(GPA)和显微镜下多血管炎(MPA)患者,比较利妥昔单抗(RTX)与环磷酰胺(CYC)诱导治疗的疗效与毒性。诱导后缓解率两组无显著差异(总体63%,OR 1.07,95%CI 0.45-2.52),因不良事件住院率RTX组22% vs CYC组10%(OR 2.27,95%CI 0.73-7.05),12个月中位儿童血管炎损害指数(pVDI)评分两组均为1(OR 0.98,95%CI 0.43-2.22)。
要点
- 儿童期GPA和MPA诱导治疗中,RTX与CYC的缓解率无显著差异(总体63%,OR 1.07,95%CI 0.45-2.52)。
- 因不良事件住院率RTX组22% vs CYC组10%(OR 2.27,95%CI 0.73-7.05),未达统计学显著。
- 12个月中位pVDI评分两组均为1(OR 0.98,95%CI 0.43-2.22),器官损害无显著差异。
核心结论
- 这是首个比较CYC与RTX用于儿童GPA和MPA诱导治疗的研究,缓解率、严重不良事件或器官损害方面均未显示显著差异。
研究设计与样本
- 基于儿童血管炎登记(ARChiVe)的队列研究,纳入104例接受RTX或CYC诱导治疗的GPA和MPA患者。
- 采用儿童血管炎活动性评分(PVAS)和儿童血管炎损害指数(pVDI)评估疾病活动度和损害。
- RTX与CYC比较采用逻辑回归分析诱导后缓解(PVAS=0)或低疾病活动度(PVAS≤2)主要结局。
主要发现
- 104例患者中43%接受RTX,46%接受CYC,11%两者均用。
- 治疗组间诊断时PVAS和发病年龄无显著差异。
- 诱导后缓解率总体63%,组间无差异(OR 1.07,95%CI 0.45-2.52)。
- 因不良事件住院:RTX组22% vs CYC组10%(OR 2.27,95%CI 0.73-7.05)。
- 12个月中位pVDI评分两组均为1(OR 0.98,95%CI 0.43-2.22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏标准化治疗方案。
- 回顾性研究。
- 缺乏纵向药物相关不良事件数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are chronic life-threatening vasculitides requiring substantial immunotherapy. Adult trials identified rituximab (RTX) as an alternative to cyclophosphamide (CYC) for remission induction of GPA and MPA. Disease rarity has limited feasibility of similar trials with pediatric patients. We aim to evaluate the relative efficacy and toxicity of CYC and RTX for patients with childhood GPA and MPA through registry-based comparative evaluation. METHODS: From A Registry of Childhood Vasculitis, we identified patients with GPA and MPA who received induction with RTX or CYC. Pediatric Vasculitis Activity Score (PVAS) and Pediatric Vasculitis Damage Index (pVDI) score evaluated disease activity and damage. Descriptive statistics summarized patient characteristics. RTX and CYC comparisons used logistic regression for primary outcomes of postinduction remission (PVAS = 0) or low disease activity (PVAS ≤ 2). Hospital admission for adverse events and pVDI scores were compared using logistic regression and ordinal regression, respectively. RESULTS: Among 104 patients, 43% received RTX, 46% CYC, 11% both. Treatment groups did not significantly differ for diagnosis PVAS and onset age. There was no difference in remission among the groups (63% overall; odds ratio [OR] 1.07, 95% confidence interval [CI] 0.45-2.52). Hospitalizations occurred in 22% of patients receiving RTX versus 10% patients receiving CYC (OR 2.27, 95% CI 0.73-7.05). The median 12-month pVDI score was 1 in both groups (OR 0.98, 95% CI 0.43-2.22). CONCLUSION: This is the first study comparing CYC and RTX for induction in pediatric GPA and MPA. No significant differences were shown in rates of remission, severe adverse events, or organ damage. Limitations included lack of standardized treatment regimens, retrospectivity, and lack of longitudinal adverse drug-related event data.
引用
- Gagne SJ, Sivaraman V, Bosman ES, et al. Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). 2024. PMID: 39467015. doi:10.1002/acr.25455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。